0 comments Monday, May 4, 2009

Featured below is an interactive Google map pinpointing outbreaks of H1N1 swine flu in 2009, together with source attributions, report dates, and current known statuses. This map is updated throughout the day with the latest suspected and confirmed cases of swine flu, as reports come in. Please note that this swine flu map is not owned or updated by Medical News Today staff and, therefore, we cannot guarantee the accuracy of the information provided by it.

How to use the H1N1 map

You can zoom in and out and scroll around to view any country that you like, or any region that you like. To view information on a specific case, simply click on a map marker.

Swine Flu Map

This Swine flu map was created by L R - a computer scientist working in the UK, together with a team of 18 other people.

Swine Flu Map - Key
  • Red markers are confirmed infections of swine flu H1N1
  • Pink markers are probable infections
  • Black markers are confirmed deaths
  • Grey markers are unconfirmed deaths
  • Blue markers are influenza-like illness

Click on any marker to view information on that case.


View 2009 Swine Flu (H1N1) Outbreak Map in a larger map

1 comments

Family members of children diagnosed with non-alcoholic fatty liver disease (NAFLD) should be considered at high risk for the disease and tested for it as part of a routine medical examination, even if they don't show symptoms, according to a recent study by researchers at the University of California, San Diego School of Medicine. The results will be published in the May edition of the journal Gastroenterology.

"As we suspected, NAFLD is not simply about weight, but rather is highly familial and likely genetic," said principal investigator Jeffrey B. Schwimmer, MD, associate professor of pediatrics and director of the Fatty Liver Clinic at Rady Children's Hospital San Diego.

NAFLD is now the most common cause of chronic liver disease is the United States. NAFLD refers to a spectrum of liver disease that begins with liver cells abnormally storing fat, in the absence of chronic alcohol use. NAFLD can be mild in some people, but in a subset with the progressive form (steatoehepatitis or NASH) there is risk for cirrhosis, liver cancer, and liver-related death. Based upon clinical observation, doctors have speculated that NAFLD may be a genetic disease, but lacked scientific support for this idea.

The current study takes a major step in building the case that NAFLD is a genetic disease. The research team studied 44 children with and without NAFLD and 152 family members of these children. In order to determine the amount of fat in the liver of each participant they used a state of the art magnetic resonance imaging (MRI) technique developed at UC San Diego. The researchers also performed tests to exclude other factors that can cause a fatty liver other than NAFLD.

The researchers found that whether or not a given person had NAFLD was highly heritable whether or not the child had NAFLD was a major determinant of the amount of liver fat present in the other family members. In the families of overweight children without NAFLD, siblings and parents had NAFLD at rates that were similar to the background population's rates of NAFLD. The rates of NAFLD were much higher in family members of children with NAFLD; it was present in 59% of siblings and 78% of parents. In most cases the person did not know that they had the disease. In a few cases the disease was already very advanced even in the absence of symptoms.

"Being overweight is a risk factor for NAFLD, but this is strongly modified by the underlying genetics," said Schwimmer. "So some people can have high body weights without any storage of fat in the liver. But in susceptible families, there's an additive effect. Regardless of weight, they are more likely to have NAFLD for genetic reasons. In addition, the more overweight such a person is, the more likely they are to have dangerous amounts of fat in their liver."

The researchers recommend that if one family member tests positive for NAFLD, other family members should talk to their doctors immediately. Early detection could catch NAFLD at a stage where the disease is reversible and further complications may be prevented before cirrhosis sets in.

Schwimmer hopes that further studies will disclose specific genetic and environmental factors that influence the development and severity of the disease, which could provide helpful information to a wide array of health care practitioners.

"Understanding that this disease runs in families may help an entire family create a healthy lifestyle with regular exercise and a heart-healthy liver healthy diet," said Schwimmer.

After participating in the study, Susanne Hernandez and her family have already changed the way they live. Like so many children with NAFLD, her 12 year-old son was identified on accident. Because of his asthma, he was scheduled to participate in a clinical trial for asthma management, but first had screening blood tests including an ALT. This test led to evaluation by a gastroenterologist and the surprising finding of severe liver disease. A quick web search led to the family becoming part of Schwimmer's research. Debbie, her son and her husband are now being treated for liver disease. Luckily, their daughter is not affected.

"This study made us more aware that we have to make changes," explained Hernandez. "After getting proper attention, my son is much more alert, and we pay attention to his fatigue, keeping him hydrated and we're on a good nutrition routine."

Previous studies by UC San Diego investigators showed that:

-- NAFLD is present in 9.6 percent of the children and adolescents living in San Diego County

-- Nearly all children with NAFLD are insulin resistant

In children, NAFLD is a major risk factor for and cardiovascular disease.

Additional contributors include Manuel Celedon, Joel Lavine, MD, PhD, UCSD department of pediatrics; Takeshi Yokoo, MD, Masoud Shiehmorteza, Michael S. Middleton, MD, PhD, and Claude B. Sirlin, M.D., and Alyssa Chavez, UCSD department of radiology; Rany Salem, PhD, Nzali Campbell, PhD and Nicholas Schork, PhD, Scripps Health and The Scripps Research Institute.

This work was funded by grants from the National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Center of Minority Health and Health Disparities and the National Center for Research Resources.

Source: University of California, San Diego

0 comments

It is well known that non-cardiac chest pain is closely related to gastroesophageal reflux diseases (GERD). Chest pain of esophageal origin can be difficult to distinguish from that caused by cardiac ischemia because the distal esophagus and the heart share a common afferent vagal supply, and GERD can cause episodes of non-cardiac chest pain that resemble ischemic cardiac pain.

A research team led by Dr. Yoshihisa Urita from Toho University School of Medicine investigated the association between gastroesophageal reflux diseases (GERD) and coronary heart diseases. Their study was published on April 14, 2009 in the World Journal of Gastroenterology.

One thousand nine hundred and seventy consecutive patients were enrolled in this study. All of the patients who first attend their hospital were asked to respond to the F-scale questionnaire regardless of their chief complaints. All patients had a careful history taken, and resting echocardiography (ECG) was performed by physicians if the diagnostic necessity arose. Patients with ECG signs of coronary artery ischemia were defined as ST segment depression based on the Minnesota code.

Among 712 patients (36%) with GERD, ECG was performed in 171 (24%), and ischemic changes were detected in eight (5%). Four (50%) of these patients with abnormal findings upon ECG had no chest symptoms such as chest pain, chest oppression, or palpitations. These patients (0.6%; 4/712) were thought to have non-GERD heartburn, which may be related to ischemic heart disease. Of the 281 patients who underwent ECG and did not have GERD symptoms, 20 (7%) had abnormal findings upon ECG. In patients with GERD symptoms and ECG signs of coronary artery ischemia, the prevalence of linked angina was considered to be 0.4% (8/1970 patients).

The study results suggest that an extra-esophageal condition causes GERD symptoms and that angina may be misclassified as GERD. Since patients with GERD have an increased risk of angina pectoris in the year after GERD diagnosis, physicians have to be concerned about missing clinically important CAD while evaluating patients for GERD symptoms.

Reference: Kato H, Ishii T, Akimoto T, Urita Y, Sugimoto M. Prevalence of linked angina and gastroesophageal reflux disease in general practice. World J Gastroenterol 2009; 15(14): 1764-1768. http://www.wjgnet.com/1007-9327/15/1764.asp

Correspondence to: Dr. Yoshihisa Urita, Department of General Medicine and Emergency Care, Toho University School of Medicine, Omori Hospital, 6-11-1, Omori-Nishi, Ota-Ku, Tokyo

Source:
Lai-Fu Li
World Journal of Gastroenterology

0 comments

Scientists at The University of Nottingham are investigating whether stem cell markers could have a role to play in speeding up wound healing in patients suffering from inflammatory bowel disease (IBD).

The study could eventually lead to the development of new drugs which use natural molecules to spark the recovery of patients suffering from ulcerative colitis and Crohn's disease, reducing their risk of associated complications such as scarring, bowel obstructions and tumour growth.

Funded with a £118,500 grant from the National Association for Colitis and Crohn's Disease (NACC), the two-year project is being led by Professor Mohammad Ilyas in the University's Division of Pathology.

He said: "The study will focus on the molecule CD24 which is a stem cell marker and which plays a key role in cell proliferation and the migration of healthy cells to a damaged area to restore normal tissue.

"CD24 is a small molecule attached to the cell membrane which has been recently reported as a marker of stem cells in the colon. It occurred to us that CD24 might have a role to play in IBD and during further studies we found that it was indeed present in sections of diseased bowel."

IBD affects around one in 400 people in the UK. Common symptoms include inflammation and ulceration of the intestine and colon, pain, severe diarrhoea, tiredness and weight loss. The cause of the disease is yet to be definitively identified, although scientists believe it could be due to a combination of genetic predisposition and environmental factors. Currently, there is no cure and patients manage their condition with a mixture of lifestyle changes, anti-inflammatory drugs and, in severe cases, surgery.

Professor Ilyas added: "The power of the gut to heal the damage caused by acute episodes of inflammation is remarkable and frequently the gut lining reverts to normal. Anti-inflammatory drugs help this process along and allow the wound healing to begin earlier than it would naturally.

"In the future, it may be possible to use a variety of therapies (possibly including gene therapy) to manipulate the expression of the CD24 molecules on cells to promote even more rapid healing. This may mean less scarring, bowel obstruction and fistulation and less chance of developing tumours resulting from persistent inflammation. As a result of this, it may also reduce the chance of needing surgery further down the line."

In the early stages of the project, the pathologists will be using cell lines in the lab to study CD24 at a cellular and molecular level to discover the mechanisms by which it operates and encourages cell migration and other associated molecules that are co-expressed.

They will then examine diseased IBD tissue to establish whether what they have observed in the lab is occurring in reality.

It is hoped the findings will lead to further clinical work to look at the possible benefits of CD24 in allowing IBD patients to more effectively manage their disease.

The CEO of NACC, Richard Driscoll, explains, "Since 1984, NACC members have raised over £4.5 million and more than 100 research awards have been made to hospitals and universities throughout the United Kingdom. This year our Medical Research Committee selected three studies to receive NACC research awards which we hope will contribute to finding improved treatments and ultimately a cure for IBD. We welcome Professor Ilyas' work on CD24 in seeking a better understanding of the gut healing process and how it may be enhanced in inflammatory bowel disease."

Source:
Professor Mohammad Ilyas
University of Nottingham

0 comments

While more than six per cent of Canadians suffer from this troublesome disease characterized by on-going abdominal pain, discomfort, bloating, and severe bouts of either diarrhoea or constipation most Canadians, including many physicians, know little about it.

New Canadian research is exploring the causes of this disease, including bacterial infections from food or water poisoning, which lead to a chronic low-level infection that in turn results in IBS symptoms. The research is also providing some hope for potential cures, including the use of probiotics and treatments to reduce stress levels.

Experts:

The following CIHR-funded researchers are available to talk about IBS:

How pathogenic bacteria act to survive and thrive in the gut and how certain treatments, like probiotic yogurt can thwart them

Dr. Philip Sherman, Scientific Director, CIHR-Institute of Nutrition, Metabolism, and Diabetes (Toronto)

How food or water poisoning, can trigger chronic IBS, and on the potential of probiotics to treat it.
Dr. Stephen Collins, McMaster University (Hamilton)

The role of sex hormones in women suffering from IBS pain.
Dr. Serge Marchand, Sherbrooke University

How gut talks and listens to the brain and spinal cord and how the gut uses cannabinoids (chemicals related to the active ingredient in marijuana) to control its movements and sensations - including pain.
Dr. Keith Sharkey, Hotchkiss Brain Institute, University of Calgary

How food and stress interact as triggers to exacerbate IBS, and how low levels of inflammation may persist and contribute to IBS symptoms even though the bowel appears to be normal.
Dr. Stephen Vanner, Queen's University. (Kingston)

The Canadian Institutes of Health Research (CIHR) is the Government of Canada's agency for health research. CIHR's mission is to create new scientific knowledge and to enable its translation into improved health, more effective health services and products, and a strengthened Canadian health-care system. Composed of 13 Institutes, CIHR provides leadership and support to nearly 12,000 health researchers and trainees across Canada.

Source: Canadian Institutes of Health Research (CIHR)